The cancer tissue page shows antibody staining in 20 different cancers. The overall cancer tissue staining statistics shows the fraction of patient samples with strong, moderate, weak or no staining (as described by the color-coding scale in the box to the right), using all the available antibodies to the protein targets encoded by this gene. The assay and annotation is described here.
The cancers can be ordered histologically or alphabetically.
For each cancer, the staining for each available antibody is reported as the fraction of samples with strong, moderate, weak or no staining (as described by the color-coding scale in the box to the right). The lenght of the bar represents the number of patient samples analysed (max=12 patients). By clicking on a cancer tissue, the detailed staining data for that cancer is available, including annotated images.
At the bottom of this page, a summary for the cancer staining for each antibody is given, together with the immunohistochemistry validation score for that antibody.
Liver, testis and urothelial cancers showed moderate cytoplasmic positivity. Remaining malignancies were generally negative or weak.
Malignant glioma, lymphoma and melanoma along with a few cases of liver, urothelial and endometrial cancers displayed weak to moderate cytoplasmic staining. Serous cystadenocarcinoma of ovary was moderately stained in the cytoplasmic membrane. Remaining malignant cells were negative.
Malignant lymphomas, melanomas, thyroid and skin cancers along with several malignant gliomas, ovarian, cervical and lung cancers showed weak to moderate membranous and cytoplasmic immunoreactivity. Remaining malignancies were in general negative.
Malignancies displayed mainly weak to moderate cytoplasmic and membranous immunoreactivity. Lymphomas and gliomas were generally negative.
Most of the cancer tissues displayed moderate to strong cytoplasmic positivity. Malignant carcinoids, gliomas, colorectal, breast, prostate and gastric cancers were weakly stained or negative.
Validation
The multi-targeting antibody yielding a staining pattern consistent with gene/protein characterization data for all of the genes
Two (or more) antibodies yielding similar staining patterns which are partly consistent with gene/protein characterization data or consistent with limited gene/protein characterization data
Two (or more) antibodies yielding similar staining patterns which are partly consistent with gene/protein characterization data or consistent with limited gene/protein characterization data
Two (or more) antibodies yielding similar staining patterns which are partly consistent with gene/protein characterization data or consistent with limited gene/protein characterization data
Two (or more) antibodies yielding similar staining patterns which are partly consistent with gene/protein characterization data or consistent with limited gene/protein characterization data
